Dr MAK Lung Yi, Loey

Dr Loey Mak

Clinical Assistant Professor

  • MBBS(HK), MRCP(UK), PDipID (HK), FHKCP, FHKAM (Medicine)
email lungyi@hku.hk
email 2255-4704
email ORCID
Biography
Dr Mak received her medical education at The University of Hong Kong. She obtained her qualification of the Membership of the Royal Colleges of Physicians of the United Kingdom in 2013 and the Postgraduate Diploma in Infectious Diseases by The Li Ka Shing Faculty of Medicine of The University of Hong Kong in 2015. She completed her specialty training in Gastroenterology and Hepatology in year 2018 and Advanced Internal Medicine in year 2019 at Queen Mary Hospital.

Dr Mak’s research interests include chronic hepatitis B, fibrosis assessment and treatment of chronic liver diseases, and biomarkers in gastrointestinal diseases. She has published more than 50 peer-reviewed articles in reputable journals. Highlights include original article and review article in Journal of Hepatology (impact factor 20.582), Hepatology (impact factor 14.679), invited editorials in Lancet Gastroenterology & Hepatology (impact factor 12.85),  Alimentary Pharmacology & Therapeutics (impact factor 7.35) and the 'Joint recommendations on management of anaemia in patients with gastrointestinal bleeding in Hong Kong' as first author, on behalf of The Hong Kong Society of Gastroenterology, The Hong Kong IBD Society, The Hong Kong Society of Digestive Endoscopy, and The Hong Kong Red Cross Blood Transfusion Service, which was published in The Hong Kong Medical Journal.

Dr Mak has received numerous academic awards, including the Dr Kate Cheng Memorial Prize for Postgraduate Diploma in Infectious Diseases, the Best Abstract in Clinical Medicine in the Medical Research Conference organized by The University of Hong Kong in 2017, 2019 and 2020, and 2021, the Young Investigators Award in the Asian Pacific Association of Gastroenterology 3rd Clinical Forum on Inflammatory Bowel Disease in 2018, and the travel award for the 7th Annual Meeting of Asian Organization of Crohn's & Colitis. She was also awarded the Faculty Knowledge Exchange Award by Li Ka Shing Faculty of Medicine, The University of Hong Kong in 2019. She won the Young Investigator’s Award in the 30th Conference of the Asian Pacific Association for the Study of the Liver, and the Distinguished Research Paper Award by the Hong Kong College of Physicians in year 2020. She is awarded with the Croucher Foundation Fellowship for 2021/2022.

Dr Mak received the Health and Medical Research Fund in year 2019 as a principal investigator for a 3-year project studying the regression of liver fibrosis in patients with chronic hepatitis B who achieved functional cure She is currently a council member for The Hong Kong Association for the Study of Liver Diseases (HKASLD). Dr Mak was part of the organising committee for the 24th Hong Kong Medical Forum. Dr Mak has delivered several invited lectures locally, and have chaired sessions in local scientific meetings. She gave numerous presentations for her research work in a number of overseas conferences. She has enrolled in the degree of Doctor of Medicine which will be completed by year 2021.

Selected publications
  1. Mak LY, Cloherty G, Wong DKH, Gersch J, Seto WK, Fung J, Yuen MF. HBV RNA profiles in chronic hepatitis B patients under different disease phases and anti-viral therapy. Hepatology 2020 [in press]
  2. Mak LY, Yuen MF, Seto WK. Letter regarding “A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement”. J Hepatol 2020 [in press]
  3. Mak LY, Wong DKH, Pollicino T, Raimondo G, Hollinger FB, Yuen MF. Occult hepatitis B infection and hepatocellular carcinoma: epidemiology, virology, hepatocarcinogenesis and clinical significance. J Hepatol 2020; 73:952-64.
  4. Mak LY, Hui RWH, Fung J, et al. Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B. J Hepatol 2020; 73:800-806.
  5. Mak LY. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide: perhaps not as simple as we thought. Lancet Gastroenterol Hepatol 2020 [in press]
  6. Mak LY. Editorial: can hepatitis B core-related antigen be the new biomarker for hepatocellular carcinoma in nucleoside analogue-treated chronic hepatitis B? Aliment Pharmacol Ther. 2019; 49(7):954-955.
  7. Mak LY, Cruz-Ramon V, Chinchilla-Lopez P, et al. Global epidemiology, prevention, and management of hepatocellular carcinoma. Am Soc Clin Oncol Educ Book 2018; 38:262-279.
  8. Mak LY, Law CW, Hui YT, et al. Joint recommendations on management of anaemia in patients with gastrointestinal bleeding in Hong Kong. Hong Kong Med J 2018; 24(4): 416-22.
  9. Mak LY, Wong DK, Cheung KS, et al. Role of serum M2BPGi levels on diagnosing significant liver fibrosis and cirrhosis in treated patients with chronic hepatitis B virus infection. Clin Transl Gastroenterol. 2018;9(6):163.
  10. Mak LY, Wong DK, Cheung KS, Seto WK, Lai CL, Yuen MF. Hepatitis B core-related antigen (HBcrAg): an emerging marker for chronic hepatitis B virus infection. Aliment Pharmacol Ther 2017.

Grant Record
  • Health and Medical Research Fund, HK Government Food & Health Bureau, 2018 (PI)
  • Gilead Sciences Research Grant (Co-PI), 2018
  • The Li Shu Pui Medical Foundation Research Grant (PI), 2020
  • State Key Laboratory of Liver Research (The University of Hong Kong) Young Researcher Support Scheme (PI), 2020

Key Office
  • Council Member, The Hong Kong Association for Study of Liver Disease
  • Associate Member, State Key Laboratory of Liver Research, The University of Hong Kong
  • Member, Junior Editorial Board, Hepatoma Research